{"organizations": [], "uuid": "aa93e9f946c319c4fbadd1961335bb0618b60ef1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/19/pr-newswire-management-change-in-moberg-pharma.html", "country": "US", "domain_rank": 767, "title": "Management Change in Moberg Pharma", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-19T11:41:00.000+03:00", "replies_count": 0, "uuid": "aa93e9f946c319c4fbadd1961335bb0618b60ef1"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/19/pr-newswire-management-change-in-moberg-pharma.html", "ord_in_thread": 0, "title": "Management Change in Moberg Pharma", "locations": [], "entities": {"persons": [{"name": "kjell rensfel", "sentiment": "negative"}, {"name": "kjell", "sentiment": "none"}, {"name": "peter wolpert", "sentiment": "none"}, {"name": "kjell rensfeldt", "sentiment": "none"}], "locations": [{"name": "moberg pharma stockholm", "sentiment": "none"}], "organizations": [{"name": "moberg pharma ab", "sentiment": "negative"}, {"name": "eu", "sentiment": "none"}, {"name": "moberg pharma", "sentiment": "none"}, {"name": "vp research and development", "sentiment": "none"}, {"name": "ceo moberg pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "STOCKHOLM, April 19th, 2018 /PRNewswire/ --\nMoberg Pharma AB (OMX: MOB) announces that Kjell Rensfeldt, VP Research and Development, will retire in the fall but remain with the company part-time as Senior Adviser.\nOn October 1st 2018, Kjell Rensfeldt, VP Research and Development, will retire from Moberg Pharma, but remain with the company in a part-time role as Senior Adviser. The process of finding his replacement has started.\n\"With extensive knowledge and experience, Kjell has contributed to the evolution of Moberg Pharma, especially through the development of Kerasal NailÂ® and MOB-015, where he has been instrumental. I've had the pleasure of working with Kjell since 2007 and I am highly grateful for his efforts over the years. I look forward to continuing our collaboration in his role as Senior Advisor to the company\", says Peter Wolpert, CEO Moberg Pharma.\nAbout this information\nThis information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 9.30 a.m. CET on April 19th, 2018.\nFor additional information, please contact:\nPeter Wolpert, CEO, telephone: +1 908 432 22 03 (US), +46 70 735 71 35, e-mail: peter.wolpert@mobergpharma.se\nAnna Ljung, CFO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se\nThis information was brought to you by Cision http://news.cision.com\nhttp://news.cision.com/moberg-pharma/r/management-change-in-moberg-pharma,c2498924\nThe following files are available for download:\nhttp://mb.cision.com/Main/1662/2498924/824486.pdf\nManagement change in Moberg Pharma\nView original content: http://www.prnewswire.com/news-releases/management-change-in-moberg-pharma-300632841.html\nSOURCE Moberg Pharma", "external_links": ["http://news.cision.com/", "http://mb.cision.com/Main/1662/2498924/824486.pdf", "http://news.cision.com/moberg-pharma/r/management-change-in-moberg-pharma,c2498924", "http://www.prnewswire.com/news-releases/management-change-in-moberg-pharma-300632841.html"], "published": "2018-04-19T11:41:00.000+03:00", "crawled": "2018-04-19T14:17:16.007+03:00", "highlightTitle": ""}